DexCom (DXCM) offers strong growth, high profitability, and reasonable valuation, fitting the "Affordable Growth" investment strategy for long-term gains.
The global healthcare industry is currently in the midst of a profound metamorphosis, characterized by a rapid influx of technological innovation, significant shifts in policy, and evolving patient expectations. This dynamic environment is not merely reshaping how medical services are delivered, but fundamentally redefining the entire patient experience and the
After years of being overshadowed by their large-cap growth counterparts, small-cap and value stocks are experiencing a significant resurgence, signaling a potential seismic shift in market leadership. This recent outperformance, particularly noticeable in the latter half of 2025, is driven by a confluence of factors including generational valuation discounts, the
Wall Street kept driving equity valuations higher on Friday, extending the momentum from Thursday when all major U.S. benchmarks closed at record highs following the Federal Reserve's rate cut.
Shares of medical device company DexCom (NASDAQ:DXCM)
fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring device, questioned its accounting, and highlighted an executive exodus.
Looking for the S&P500 stocks that are experiencing notable gaps on Friday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 16.4%.
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing.
However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.
Shares of medical device company DexCom (NASDAQ:DXCM)
jumped 2.6% in the morning session after the company announced it would present new product features and positive clinical data at the European Association for the Study of Diabetes (EASD) 2025 conference.
These two companies could present an opportunity for investors to gain access while they are relatively undervalued and before they appreciate once again.
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Shares of medical device company DexCom (NASDAQ:DXCM)
fell 2% in the morning session after Oppenheimer downgraded the stock to Perform from a previous Outperform rating.
Shares of medical device company DexCom (NASDAQ:DXCM)
jumped 3.3% in the afternoon session after company executives provided an optimistic outlook at the Wells Fargo Healthcare Conference on Wednesday.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Wednesday as we examine the latest happenings in today's session.
